Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study-Reference-Cited by-同舟云学术

Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study

Published:2018-12 Issue:6 Volume:79 Page:1047-1052
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Min Lee Charles Kyung,Li Shufeng,Tran Duy Cong,Zhu Gefei Alex,Kim Jinah,Kwong Bernice Y.,Chang Anne Lynn S.

Publisher

Elsevier BV

Subject

Dermatology

Reference19 articles.

1. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma;Hamid;N Engl J Med,2013

2. Atezolizumab in advanced non-small lung cancer;Ilie;J Thorac Dis,2017

3. The B7-H1 (PD-L1) T lymphocyte inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors;Ghebeh;Neoplasia,2006

4. Programmed cell death1ligand1and tumor infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer;Hamanishi;Proc Natl Acad Sci U S A,2007

5. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance;Wu;Acta Histochem,2006

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer Therapy-induced Dermatotoxicity as a Window to Understanding Skin Immunity;Hematology/Oncology Clinics of North America;2024-10

2. Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update;Journal for ImmunoTherapy of Cancer;2024-07

3. Immune Checkpoint Inhibitor-Induced Psoriasis;Dermatologic Clinics;2024-07

4. Immune-related dermatological adverse events of antitumor immunotherapy with PD-1, PD-L1, CTLA-4 inhibitors;Russian Journal of Skin and Venereal Diseases;2024-05-14

5. Network pharmacology and molecular docking to explore the mechanism of a clinical proved recipe for external use of clearing heat and removing dampness in the treatment of immune-related cutaneous adverse events;Medicine;2024-03-15